Repertoire Immune Medicines signed a multi‑billion‑dollar partnership with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving an $85 million upfront payment and up to $1.84 billion in downstream milestones plus royalties. The deal expands Repertoire’s commercialization partnerships—adding Lilly to a roster that already includes Bristol Myers Squibb and Genentech—and validates Repertoire’s Decode platform for mapping immune specificity and designing antigen‑targeted therapeutics.